Tianjin Chase Sun Pharmaceutical Co.,Ltd Stock price

Equities

300026

CNE100000GF1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-22 pm EST 5-day change 1st Jan Change
3.95 CNY +0.25% Intraday chart for Tianjin Chase Sun Pharmaceutical Co.,Ltd +1.02% -6.84%
Sales 2023 * 6.67B 927M Sales 2024 * 7.45B 1.04B Capitalization 11.87B 1.65B
Net income 2023 * 530M 73.67M Net income 2024 * 706M 98.13M EV / Sales 2023 * 1.78 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.59 x
P/E ratio 2023 *
21.9 x
P/E ratio 2024 *
16.5 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 27.5%
More Fundamentals * Assessed data
Dynamic Chart
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Chase Sun Pharma’s Muscle Relaxant Passes Drug Consistency Test MT
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd. Approves Final Cash Dividend for A Shares for the Year 2022, Payable on 12 May 2023 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Profit Distribution Proposal for 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces Profit Distribution Proposal for 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 19, 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Profit Distribution Proposal for 2021 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Cash Dividend for 2021 CI
Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+0.25%
1 week+1.02%
Current month+10.03%
1 month+5.33%
3 months-18.39%
6 months-6.62%
Current year-6.84%
More quotes
1 week
3.82
Extreme 3.82
3.97
1 month
3.07
Extreme 3.07
4.09
Current year
3.07
Extreme 3.07
4.39
1 year
3.07
Extreme 3.07
6.68
3 years
3.07
Extreme 3.07
9.90
5 years
3.07
Extreme 3.07
9.90
10 years
2.92
Extreme 2.92
10.93
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 49 -
Director/Board Member 55 -
Members of the board TitleAgeSince
Founder 59 96-09-22
Director/Board Member 63 20-11-17
Director/Board Member 61 20-01-15
More insiders
Date Price Change Volume
24-02-23 3.95 +0.25% 48,682,400
24-02-22 3.94 +1.03% 47,455,090
24-02-21 3.9 -0.26% 57,651,600
24-02-20 3.91 +1.03% 47,369,950

End-of-day quote Shenzhen S.E., February 22, 2024

More quotes
Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.95 CNY
Average target price
4 CNY
Spread / Average Target
+1.27%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd - Shenzhen S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer